NDA 215206 · Abbvie
Qulipta
Atogepant · Oral · Calcitonin Gene-related Peptide Receptor Antagonist
NovelPriority reviewCDER novel approval, Sep 28, 2021: To prevent episodic migraines
Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Sep 28, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
23
17 Phase 3, 7 recruiting
FAERS reports
6,969
2,589 serious, 83 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 30, 2025.
QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )
Mechanism: Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 17, 2023 Supplement 4 · Efficacy Label
- Sep 28, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
3 products under this application
- QULIPTA · ATOGEPANT 30MG · TABLET, ORAL · Prescription
- QULIPTA · ATOGEPANT 60MG · TABLET, ORAL · Prescription
- QULIPTA · ATOGEPANT 10MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atogepant" as an intervention, any sponsor and status, largest first.
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigrainePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT06241313 · 2,158 participants · Start Mar 25, 2024 · Primary completion Jul 7, 2025
Drug: Atogepant; Placebo for Atogepant · For: Migraine
Sites: Edegem, Belgium; Jette, Belgium; Saint-Nicolas, Belgium · 149 sites in all
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06972056 · 1,335 participants (planned) · Start Jul 9, 2025 · Primary completion Mar 1, 2029
Drug: Atogepant 60 mg; Propranolol 160 mg and 1 more · For: Migraine
Sites: Hazel Green, Alabama; Flagstaff, Arizona; Phoenix, Arizona · 39 sites in all
- 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03777059 · 910 participants · Start Dec 14, 2018 · Primary completion Jun 19, 2020
Drug: Atogepant; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Glendale, Arizona; Phoenix, Arizona · 138 sites in all
- Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine PreventionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02848326 · 834 participants · Start Sep 6, 2016 · Primary completion Apr 2, 2018
Drug: Atogepant; Placebo-matching Atogepant · For: Migraine, With or Without Aura
Sites: Birmingham, Alabama; Chandler, Arizona; Carlsbad, California · 75 sites in all
- Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03855137 · 778 participants · Start Mar 11, 2019 · Primary completion Jan 20, 2022
Drug: Atogepant 30 mg; Atogepant 60 mg and 1 more · For: Chronic Migraine
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fresno, California · 150 sites in all
- Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03700320 · 744 participants · Start Oct 8, 2018 · Primary completion May 21, 2020
Drug: Standard of Care (SOC) Migraine Preventive Medication; Atogepant · For: Episodic Migraine
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 112 sites in all
- Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigrainePivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT03939312 · 685 participants · Start May 6, 2019 · Primary completion Mar 31, 2021
Drug: Atogepant · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Tucson, Arizona · 113 sites in all
- Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigrainePivotal-lookingEnrolling by invitation
AbbVieAbbVie (ABBV)
NCT05707949 · 650 participants (planned) · Start Jun 5, 2023 · Primary completion Apr 2032
Drug: Atogepant · For: Migraine Prophylaxis
Sites: Huntsville, Alabama; Little Rock, Arkansas; Anaheim, California · 86 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- migraine1,224
- drug ineffective829
- headache672
- nausea639
- constipation474
- fatigue446
- dizziness276
- therapy interrupted201
- pain189
- vomiting188
- off label use184
- decreased appetite182
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 8 |
| 2021 | 28 |
| 2022 | 1,687 |
| 2023 | 1,716 |
| 2024 | 999 |
| 2025 | 1,371 |
| 2026 | 1,155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Qulipta (Atogepant)
2024 spending
$260M
Beneficiaries
45,046
209,816 claims
Per beneficiary
$5,779
$35.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,338,319 |
| 2022 | $51,325,273 |
| 2023 | $137,880,798 |
| 2024 | $260,307,144 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Atogepant for the Preventive Treatment of Migraine.
Ailani J, Lipton RB, Goadsby PJ, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F, Puledda F, Garcia-Azorin D, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- CGRP-targeted medication in chronic migraine - systematic review.
Oliveira R, Gil-Gouveia R, Puledda F · J Headache Pain 2024 · Systematic Review
- Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Pozo-Rosich P, Ailani J, Ashina M, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
Messina R, Huessler EM, Puledda F, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
Tassorelli C, Nagy K, Pozo-Rosich P, et al. · Lancet Neurol 2024 · Clinical Trial, Phase III, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.